Project Details
| Short title | ERAS-254-01 |
|---|---|
| Acronym | SEACRAFT-1 |
| Status | Active |
| Effective start/end date | 27/02/24 → 26/02/29 |
CTU: An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations [SEACRAFT-1]
- Park, John (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Chester, Catherine (Clinical Trial Unit Staff)
Project: Research